Avirmax Inc. Announces Publication in Genetic Engineering & Biotechnology News
-Overcoming Biosafety Challenges posed by Viral Vectors through Bac-to-AAV, 2D-HPLC, QbD, LC-MS/MS, and other Technologies
HAYWARD, CA [December 9, 2021]—Dr. Shawn (Shengjiang) Liu, President and CEO of Avirmax, Inc., in San Francisco Bay Area, today announced technical contributions and collaboration with Dr. Kathy Liszewski, Assistant Professor of Medicine at Washington University School of Medicine in St. Louis.
Avirmax Presents Simple and Robust Technology Platform for AAV Production
Presentation Detailing Bac-to-AAV Sf9 Platform High-Titer, Downstream Purity and Safety
HAYWARD, Calif., [October 18, 2021]—Dr. Shawn (Shengjiang) Liu, President and CEO of Avirmax, Inc., a San Francisco Bay Area Gene Therapy company, presented “A Simple and Robust rAAV Manufacturing System to Achieve High Titer and Quality Gene Therapy Vectors” during the BioProcessing International Conference at the Boston Convention and Exhibition Center and online.